Equites Radar

NOVT · Novanta Inc.

Scientific & Technical InstrumentsUnited StatesAnalyst view: Strong Buy

$146.56

+1.84% last session

End-of-day data · close of 2026-09-11

Mildly bullish3 bullish · 1 bearish technical signals
Consensus: Strong Buy (1.33 from 2 analysts)
To mean target: +35.2%

Market cap

$5B

Enterprise value

$5B

Trailing P/E

91.7

Forward P/E

33.0

Dividend yield

Beta

1.68

Avg volume

0M

Employees

3K

Daily Change %

1.84%

5 Days Change

-1.75%

10 Days Change

-0.31%

30 Days Change

-13.09%

60 Days Change

-6.95%

Month to Day Change

1.45%

Year to Day Change

22.50%

Analyst Outlook

Consensus ratingStrong Buy
Recommendation mean (1–5)1.33
Covering analysts2
Mean price target$194.50
Low price target$194.00
Upside to mean target+35.2%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)47.4
50-day MA$150.10
200-day MA$138.50
Price vs 50-day MA-2.4%
Price vs 200-day MA+5.8%
MACD histogram0.09
Volume vs 3-month avg0.6×
52w low $99.2252w high $168.75

Analyst sentiment over time — NOVT

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-05-13

Latest call per bank · past 12 months

Recent rating actions

DateFirmActionRatingPrice target
2026-05-13BairdMaintainsOutperform$144 $173
2026-03-30BairdUpgradeNeutralOutperform$150 $144

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-09-11

  • RSI (14): RSI is 47 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 2.4% below the 50-day MA ($150.10).
  • Price vs 200-day MA: Trading 5.8% above the 200-day MA ($138.50).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is positive (+0.09) — short-term momentum is improving.
  • 52-week range: Price sits between the 52-week low ($99.22) and high ($168.75).

NOVT Price Chart

Loading chart for NOVT

Fundamentals

Revenue (TTM)$1.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$42.74
Net Debt / EBITDA-2.4
WACC15.0%
Revenue growth10.00%
Earnings growth150.00%

About Novanta Inc.

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

More in Scientific & Technical Instruments

Screen NOVT against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.